“Cancer Capitalism”
Bloomberg News
In this three-part series, Tanaz Meghjani, along with Robert Langreth and Anna Edney, sheds light on a critical issue often speculated about in cancer treatment. They provide evidence-based, data-driven insights on what they call “cancer capitalism,” in which the drive for profit can harm patients. The series begins with an analysis of the data behind high-cost cancer pharmaceuticals, followed by an examination of a medical device implanted in breast cancer patients that failed to dissolve as intended, and concludes with an exploration of how lower doses of $200,000 drugs may help hundreds of thousands of people around the world.
Read the Series